

产品名称: **Nedaplatin**
 产品别名: **NSC 375101D**

生物活性:				
Description	Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.			
In Vitro	<p>Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[1]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[2].</p>			
Solvent&Solubility	<p><i>In Vitro:</i> H₂O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin's activity)</p>			
	<div>Preparing Stock Solutions</div>	<div>Solvent Mass Concentration</div>	1 mg	5 mg
		1 mM	3.2984 mL	16.4919 mL
		5 mM	0.6597 mL	3.2984 mL
		10 mM	0.3298 mL	1.6492 mL
	<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。</p>			
References	<p>[1]. Kanzawa, F., et al., <u>In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.</u> Clin Cancer Res, 2001. 7(1): p. 202-9.</p> <p>[2]. Uchida, N., et al., <u>Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model.</u> Eur J Cancer, 1998. 34(11): p. 1796-801.</p>			